Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003266 · ClinicalTrials.gov registry record · Phase 3
Methylphenidate in Treating Patients With Melanoma
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00003266 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 200 participants.
The verdict
NCT00003266, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.
Interventions
- PROCEDURE quality-of-life assessment
- DRUG methylphenidate hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 1999-10-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003266
The ClinicalTrials.gov registry entry for NCT00003266 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00003266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003266 about?
NCT00003266 is a clinical study titled "Methylphenidate in Treating Patients With Melanoma". RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if me...
What is the current status of trial NCT00003266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 1999-10-12.
What interventions are being tested in trial NCT00003266?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), methylphenidate hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003266?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.